Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDCG Oncology, Inc. Common stock Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.31 | -$0.31 | -$0.31 |
| Q2 2024 | 1 | -$0.36 | -$0.36 | -$0.36 |
| Q3 2024 | 1 | -$0.35 | -$0.35 | -$0.35 |
| Q4 2024 | 2 | -$0.43 | -$0.28 | -$0.35 |
| Q1 2025 | 1 | -$0.44 | -$0.37 | -$0.41 |
| Q2 2025 | 1 | -$0.44 | -$0.44 | -$0.44 |
| Q3 2025 | 1 | -$0.46 | -$0.46 | -$0.46 |
| Q4 2025 | 1 | -$0.51 | -$0.51 | -$0.51 |
| Q1 2026 | 1 | -$0.60 | -$0.60 | -$0.60 |
| Q2 2026 | 1 | -$0.63 | -$0.63 | -$0.63 |
| Q3 2026 | 1 | -$0.58 | -$0.58 | -$0.58 |
| Q4 2026 | 1 | -$0.32 | -$0.32 | -$0.32 |
CG Oncology, Inc. Common stock Earnings Date And Information
CG Oncology, Inc. Common stock last posted its earnings results on Thursday, August 8th, 2024. The company reported $-0.28 earnings per share for the quarter, topping analysts' consensus estimates of $-0.42 by $0.14. The company had revenue of 43,000 for the quarter and had revenue of 204,000 for the year. CG Oncology, Inc. Common stock has generated $-16 earnings per share over the last year ($-15.65 diluted earnings per share) and currently has a price-to-earnings ratio of -26.61. CG Oncology, Inc. Common stock has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
CG Oncology, Inc. Common stock Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 09/30/2024 | Q3 2024 | -$0.30 | $113,000 | $43,000 | ||
| 08/08/2024 | Q2 2024 | -$0.42 | -$0.28 | 0.14 | $209,667 | $111,000 |
| 05/09/2024 | Q1 2024 | -$0.35 | -$0.36 | -0.01 | $529,000 | |
| 03/26/2024 | Q4 2023 | -$0.24 | $1,000 | |||
| 09/29/2023 | Q3 2023 | -$0.18 | $9,000 | |||
| 06/28/2023 | Q2 2023 | -$0.17 | $0 | |||
| 03/30/2023 | Q1 2023 | -$0.13 | $194,000 | |||
| 12/30/2022 | Q4 2022 | -$0.13 | $0 |
CG Oncology, Inc. Common stock Earnings: FAQ's
When is CG Oncology, Inc. Common stock's earnings date?
CG Oncology, Inc. Common stock has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates.
Did CG Oncology, Inc. Common stock beat their earnings estimates last
quarter?
In the previous quarter, CG Oncology, Inc. Common stock (:CGON) reported $-0.28 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.42 by $0.14.
How can I listen to CG Oncology, Inc. Common stock's earnings conference
call?
The conference call for CG Oncology, Inc. Common stock's latest earnings report can be listened to online.
How can I read CG Oncology, Inc. Common stock's conference call transcript?
The conference call transcript for CG Oncology, Inc. Common stock's latest earnings report can be read online.
How much revenue does CG Oncology, Inc. Common stock generate each year?
CG Oncology, Inc. Common stock (:CGON) has a recorded annual revenue of $204,000.
How much profit does CG Oncology, Inc. Common stock generate each year?
CG Oncology, Inc. Common stock (:CGON) has a recorded net income of $204,000. CG Oncology, Inc. Common stock has generated $-15.65 earnings per share over the last four quarters.
What is CG Oncology, Inc. Common stock's price-to-earnings ratio?
CG Oncology, Inc. Common stock (:CGON) has a price-to-earnings ratio of -26.61 and price/earnings-to-growth ratio is 2.35.